Ubs Asset Management Americas Inc Cardiol Therapeutics Inc. Transaction History
Ubs Asset Management Americas Inc
- $379 Billion
- Q1 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Cardiol Therapeutics Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 55,000 shares of CRDL stock, worth $68,750. This represents 0.0% of its overall portfolio holdings.
Number of Shares
55,000Holding current value
$68,750% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding CRDL
# of Institutions
42Shares Held
7.86MCall Options Held
25.9KPut Options Held
1.7K-
Tejara Capital LTD London, X03.19MShares$3.99 Million1.2% of portfolio
-
Advisor Shares Investments LLC Bethesda, MD982KShares$1.23 Million0.19% of portfolio
-
Mmcap International Inc. Spc Grand Cayman, E9783KShares$978,2810.35% of portfolio
-
Ubs Group Ag498KShares$622,3210.0% of portfolio
-
Pvg Asset Management Corp Golden, CO487KShares$609,1183.54% of portfolio
About Cardiol Therapeutics Inc.
- Ticker CRDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 61,942,500
- Market Cap $77.4M
- Description
- Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...